Market Place

Market Place

Market Place

Menu

Post Enquiry

Post Enquiry

PharmaCompass

Home

Market Place

Market Place

Search
All
API
FDF
Price
Services
Excipients
Enquiries

    Find

    • Active Pharmaceutical Ingredients Active Pharmaceutical Ingredients
    • Finished Drug Formulations Finished Drug Formulations
    • Price Price
    • Excipients Excipients
    • Services Services
    • Market Place Marketplace

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    pipeline-prospector-insert
    X

    Find Oncology Drugs in Phase II Clinical Development in SPAIN

    Loading...

    All Data

    Filters Filter refresh
    ×
    FILTER DATA :
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            Upfront Payment filter
              refresh

              Product Type Full Screen

              Companies Full Screen

              Highlight Therapeutics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SPAIN Spain

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chemspec USA 2020

              Participation Not Confirmed

              Update your events

              Highlight Therapeutics Announces First Patient Dosed in Phase IIa Study in Liver Metastasis

              Contact the Supplier

              Lead Product(s): BO-112,Pembrolizumab

              Therapeutic Area: Oncology Product Name: BO-112

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 26, 2020

              Details:

              Highlight Therapeutics dosed first patient in a Phase IIa clinical evaluation of the combination of BO-112, Highlight's lead program, and KEYTRUDA® (pembrolizumab), MSD's anti-PD-1 therapy, in patients with select advanced stage solid tumors with liver metastases.

              Oryzon Genomics

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SPAIN Spain

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chemspec USA 2020

              Participation Not Confirmed

              Update your events

              ORYZON to Present Additional Efficacy Clinical Data From ALICE Phase IIa Trial with Iadademstat

              Contact the Supplier

              Lead Product(s): Iadademstat,Azacitidine

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 02, 2020

              Details:

              ALICE is a single arm, open-label Phase IIa clinical trial to evaluate the safety, tolerability, dose finding and efficacy of iadademstat in combination with azacitidine in older patients with AML in first line therapy.

              PharmaMar

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SPAIN Spain

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chemspec USA 2020

              Participation Not Confirmed

              Update your events

              PharmaMar, Jazz Pharma Announce FDA Acceptance and Priority Review of NDA for Lurbinectedin in Relapsed Small Cell Lung Cancer

              Contact the Supplier

              Lead Product(s): Lurbinectedin

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: February 17, 2020

              Details:

              PharmaMar submitted the NDA to FDA in December 2019 based on data from the Phase II monotherapy basket trial, which included evaluation of lurbinectedin for the treatment of relapsed SCLC.

              PharmaMar

              • Development Update

              Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

              SPAIN Spain

              Post An Enquiry Post An Enquiry

              Virtual Booth Virtual Booth

              Chemspec USA 2020

              Participation Not Confirmed

              Update your events

              PharmaMar announces the initiation of a study of lurbinectedin in combination with immunotherapy

              Contact the Supplier

              Lead Product(s): Lurbinectedin,Atezolizumab

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: January 14, 2020

              Details:

              PharmaMar to start a Phase I-II study to determine the recommended dose and efficacy of lurbinectedin in combination with atezolizumab in patients with advanced Small Cell Lung Cancer (SCLC).

              PharmaCompass__DigitalAd